INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiative
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
- Stocks, bonds edge up ahead of 'formidable' week for risk
Insys Therapeutics Announces FDA Approval of Syndros™
July 5, 2016 6:55 AM EDTPHOENIX, July 05, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Insys or the Company) (NASDAQ: INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug... More



